Table 2.
Patient details and treatment regimens.
| NACP # |
Ref. # |
Age (yr) |
Pre-treatment cancer size (cm) |
Cancer stage |
Cancer subtype |
Chemotherapy agent |
Infusion Frequency (number) |
Treatment duration (weeks) |
Post-treatment cancer size (Hist.) (cm) |
NAC response |
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRI X-ray |
Optical | ||||||||||
| 1 | 164 | 38 | 9.4 | 1.2 | IIIC | ER+/HER2− | Paclitaxel | Weekly (12) | 31 | 6.0 | NR (PR2) |
| Capecitabine | Bi-weekly (5) | ||||||||||
| 2 | 163 | 72 | 3.2 | 2.1 | IIB | TNBC | Doxorubicin, Cyclophosphamide | Bi-weekly (4) | 23 | – | R (pCR) |
| Paclitaxel | Weekly (12) | ||||||||||
| 3 | 165 | 57 | 2.5 | 1.4 | IIB | ER+/HER2− | Doxorubicin, Cyclophosphamide | Bi-weekly (4) | 22 | 0.9 | R (PR1) |
| Paclitaxel | Weekly (12) | ||||||||||
| 4 | 166 | 54 | 2.9 | 1.3 | IIIA | HER2+ | Carboplatin, Docetaxel, Trastuzumab, Pertuzumab | Every 3 weeks (6) | 16 | 2.8 | NR (PR2) |
| 5 | 167 | 46 | 4.4 | 3.7 | IV | HER2+ | Carboplatin, Docetaxel, Trastuzumab, Pertuzumab | Every 3 weeks (6) | 17 | – | R (pCR) |
| 6 | 168 | 47 | 6.0 | 4.4 | IIB | TNBC | Doxorubicin, Cyclophosphamide | Bi-weekly (4) | 21 | 0.4 | R (PR1) |
| Paclitaxel w/Carboplatin (every 3rd) | Weekly (11) | ||||||||||
| 7 | 169 | 44 | 7.0 | 3.5 | IIIA | ER+/HER2− | Doxorubicin, Cyclophosphamide | Bi-weekly (4) | 16 | 0.6 | R (PR1) |
| Paclitaxel | Bi-weekly (4) | ||||||||||
| 8 | 170 | 74 | Inflam | 2.6 | IIIB | ER+/HER2− | Doxorubicin, Cyclophosphamide | Every 3 weeks (4) | 20 | 1.7 | R (PR1) |
| Paclitaxel | Weekly (8) | ||||||||||
| 9 | 171 | 44 | Inflam | 1.3 | IIIB | ER+/HER2− | Doxorubicin, Cyclophosphamide | Bi-weekly (4) | 20 | 11.3 | NR (PR2) |
| Paclitaxel | Weekly(12) | ||||||||||
| 10 | 173 | 56 | 4.5 | 1.9 | IIB | HER2+ | Carboplatin, Docetaxel, Trastuzumab, Pertuzumab | Every 3 weeks (6) | 17 | – | R (pCR) |
Note - Ref #: progressive patient number; Age: age of patient at time of baseline scan; Pretreatment cancer size: maximum tumor dimension pretreatment (one column reports the dimension from MRI or full-field digital mammography, one column reports the size of the tumor ROI from optical mammography), “Inflam” denotes inflammatory breast cancer; Cancer stage: initial clinical cancer stage; Cancer subtype: triple-negative breast cancer (TNBC), estrogen-receptor-positive/progesterone-receptor-negative (ER+/HER2−), and HER2+; Chemotherapy agent: chemotherapy drugs administered to patient; Infusion frequency (total number): how often infusions were performed (and total number of infusions); Duration of treatment: how long the patients underwent treatment (including breaks in therapy schedule); Post-treatment cancer size (Hist.): maximum tumor dimension post treatment from histology after surgical resection; Response level: individual patient’s response (R: responder showing either a pathologic complete response (pCR) [no remaining tumor] or partial response 1 (PR1) [tumor decreased by more than 50% in size]; NR: non-responder showing partial response 2 (PR2) [tumor decreased by less than 50% in size]).